Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV)
fixed-dose combination (FDC) tablet with or without ribavirin (RBV) in treatment-naive or
treatment-experienced Japanese participants with chronic genotype 1 HCV infection.
Participants receive 12 weeks of treatment and continue assessments during a 24-week
posttreatment follow-up period.